EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Emerging Antimicrobial Resistance in Gram-Negative Pathogens: Protocol for a Pragmatic Cluster-Randomized Controlled Trial

Ahsan Raza Khan, Mehwish Iqbal

Journal of Society Medicine · 31.03.2026 · 5 (3) · 81-90

DOI: 10.71197/jsocmed.v5i3.269 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Society Medicine, online erschienen am 31.03.2026. Verfasst von Ahsan Raza Khan und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Antimicrobial resistance among Gram-negative pathogens, including extended-spectrum β-lactamase (ESBL)-producing Enterobacterales and carbapenem-resistant Acinetobacter and Pseudomonas, is associated with high mortality and limited therapeutic options. Delayed initiation of effective antimicrobial therapy in bloodstream infections (BSIs) is consistently linked to adverse clinical outcomes. Although rapid diagnostic tests (RDTs) combined with antimicrobial stewardship (AS) improve the timeliness of therapy, high-quality evidence from resource-constrained settings remains limited. This study evaluates a pragmatic strategy integrating rapid diagnostics with stewardship to optimize early targeted therapy.

Methods

This multicenter, parallel-group, pragmatic cluster randomized controlled trial includes 20 hospitals randomized to either an intervention bundle or standard care. The intervention comprises PCR-based pathogen and resistance gene identification, EUCAST rapid antimicrobial susceptibility testing (RAST), and a predefined stewardship algorithm for antibiotic optimization. Standard care includes routine culture, MALDI-TOF identification, and CLSI-guided susceptibility testing. Adult patients with confirmed Gram-negative BSIs are enrolled. The primary outcome is the proportion of patients receiving optimal targeted therapy within 24 hours of culture positivity. Secondary outcomes include time to effective therapy, 30-day mortality, hospital length of stay, adverse events, and antibiotic utilization. Analyses will follow an intention-to-treat approach using mixed-effects regression models.

Results

As this manuscript presents a study protocol, no clinical outcome data are reported. Patient enrollment and trial implementation are ongoing across participating centers.

Conclusion

This rigorously designed pragmatic cluster randomized trial will generate high-quality evidence on whether integrating rapid diagnostics with antimicrobial stewardship improves timely targeted therapy in Gram-negative BSIs, with direct implications for optimizing antimicrobial use and addressing global antimicrobial resistance.

Zitieren

APA

Khan, A. R., & Iqbal, M. (2026). Emerging Antimicrobial Resistance in Gram-Negative Pathogens: Protocol for a Pragmatic Cluster-Randomized Controlled Trial. Journal of Society Medicine, 5(3), 81-90. https://doi.org/10.71197/jsocmed.v5i3.269

Vancouver

Khan AR, Iqbal M. Emerging Antimicrobial Resistance in Gram-Negative Pathogens: Protocol for a Pragmatic Cluster-Randomized Controlled Trial. Journal of Society Medicine. 2026;5(3):81-90. doi:10.71197/jsocmed.v5i3.269

BibTeX
@article{Khan2026,
  author = {Khan, Ahsan Raza and Iqbal, Mehwish},
  title = {Emerging Antimicrobial Resistance in Gram-Negative Pathogens: Protocol for a Pragmatic Cluster-Randomized Controlled Trial},
  journal = {Journal of Society Medicine},
  year = {2026},
  volume = {5},
  number = {3},
  pages = {81--90},
  doi = {10.71197/jsocmed.v5i3.269}
}
Kostenlos starten →